MONEY

UCB Announces a Head-to-Head Study Evaluating BIMZELX ® (bimekizumab) versus SKYRIZI ® (risankizumab) in Active Psoriatic Arthritis

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 30, 2024 - 20:00
UCB Announces a Head-to-Head Study Evaluating BIMZELX ® (bimekizumab) versus SKYRIZI ® (risankizumab) in Active Psoriatic Arthritis
Read More

Tags:

Previous Article

Perimeter Medical Imaging AI Announces Closing of Non-Brokered Private Placement

Next Article

China stocks surge on stimulus optimism, world stocks off record highs

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Commerzbank, UniCredit to meet Friday morning, source says

Commerzbank, UniCredit to meet Friday morning, source says

Tomas Kauer - Mode... Sep 27, 2024

Melania Trump suggests support for abortion rights in break from Donald Trump

Melania Trump suggests support for abortion rights in b...

Tomas Kauer - Mode... Oct 4, 2024

China reopens with a bang but fails to lift Asia stocks

China reopens with a bang but fails to lift Asia stocks

Tomas Kauer - Mode... Oct 8, 2024